advertisement
Abstract #70710 Published in IGR 18-2
Intraocular Pressure after Intravitreal Triesence Injection
Atchison EA; Bakri SJSeminars in Ophthalmology 2016; 0: 1-5
PURPOSE: Elevated intraocular pressure (IOP) is a frequent adverse event associated with intravitreal triamcinolone acetate injection. The incidence of elevated IOP with preserved forms of triamcinolone has been studied but the effect of preservative-free formulations has not been clinically evaluated. DESIGN: A retrospective, observational clinical study. METHODS: For patients undergoing intravitreal injections over the study period, age, sex, history of glaucoma or ocular hypertension were recorded. For each injection, preinjection IOP, maximum IOP (IOPmax), dose, and indication for injection were noted for both eyes. RESULTS: Fourteen patients received 72 injections in 18 eyes. The mean baseline IOP was 15.4 mm Hg; the mean IOPmax was 19.8 mm Hg (P<0.001), occurring 63 days after injection. Outcomes were not significantly different between patients receiving 2 or 4 mg doses. History of glaucoma did not significantly affect IOPmax. CONCLUSIONS: Eyes should be monitored for IOP rises after preservative-free triamcinolone acetonide injections.
a Department of Ophthalmology , Mayo Clinic , Rochester , MN , USA.
Full articleClassification:
9.4.1 Steroid-induced glaucoma (Part of: 9 Clinical forms of glaucomas > 9.4 Glaucomas associated with other ocular and systemic disorders)
11.15 Other drugs in relation to glaucoma (Part of: 11 Medical treatment)
